Cronobacter Infection: How to Treat
Antibiotics are typically the first line of treatment for Cronobacter infections Cronobacter infections are often treated with antibiotics, typically cefazolin and amoxicillin, which are quite effective in most cases. However, treatment can be challenging because continued use of antibiotics can lead to the development of antibiotic resistance. What are the treatment options for Cronobacter infections? […]
Patients With Head/Neck Cancer See Lower Stroke Risk With Initial Surgery
In oropharyngeal squamous cell carcinoma (OPSCC), the type of initial treatment appears to influence the likelihood of stroke in the years afterward, researchers said. A population-based study of U.S. veterans treated for OPSCC found 23% lower stroke risk for those who underwent up-front surgery compared with patients who received definitive (chemo)radiotherapy, reported Lova L. Sun, […]
Second-Line CAR-T Impresses in Transplant-Ineligible Large B-Cell Lymphoma
Treatment with second-line lisocabtagene maraleucel (liso-cel; Breyanzi) yielded a response rate of 80% for patients with relapsed or refractory large B-cell lymphoma (LBCL) who were not candidates for hematopoietic stem cell transplant, the phase II PILOT study showed. Among 61 evaluable patients with PET-positive disease, 54% achieved a complete response with the chimeric antigen receptor […]
Better Outcomes Tied to More HCV Treatment for People Who Inject Drugs
A greater uptake in hepatitis C virus (HCV) treatment for people who inject drugs (PWID) at a community center led to decreases in liver disease and mortality, a longitudinal cohort study found. Among 1,323 PWID with chronic HCV at a Baltimore community-based center, the number of those with HCV RNA declined from 100% in 2006 […]
Novel Focal Therapy Yields Low Rate of Serious Prostate Cancers
The use of a novel focal therapy technique called high-frequency irreversible electroporation (H-FIRE) for the treatment of localized prostate cancer resulted in a 6-month clinically significant prostate cancer (csPCa) rate lower than previously seen with other energy platforms, according to Chinese investigators. Among the 100 patients who received H-FIRE and were biopsied at 6 months, […]
Whopping Mortality Benefit in Severe COVID Trial
Treatment with a novel, oral microtubule disruptor significantly reduced the risk of death in hospitalized COVID-19 patients with severe disease, an interim analysis of a phase III study indicated. Mortality at 60 days, the international trial’s primary endpoint, was more than halved in the group assigned to investigational sabizabulin versus those randomized to placebo (20.2% […]
Number of U.S. Cancer Survivors Grows to 18 Million
A growing — and aging — population, combined with advances in early detection and treatment, pushed the number of cancer survivors to new heights this year. More than 18 million Americans with a history of cancer, two-thirds of them over the age of 65 years, were living in the U.S. as of January 1 of […]
FDA Advisers Reject Nuplazid for Alzheimer’s Disease Psychosis
An FDA advisory panel rejected pimavanserin (Nuplazid) for the treatment of hallucinations and delusions in patients with Alzheimer’s disease psychosis on Friday. In a vote of 9-3, the Psychopharmacologic Drugs Advisory Committee decided against recommending the drug for approval for these patients, citing a slew of shortcomings in supporting trial data. This could have been […]
Drugmaker Pulls Third-Line PARP Inhibitor Approval in Ovarian Cancer
Clovis Oncology has voluntarily withdrawn the indication for rucaparib (Rubraca) as a third-line treatment in BRCA-mutated ovarian cancer after an overall survival (OS) analysis showed a signal for potential harm, according to a filing with the Securities and Exchange Commission (SEC). “Based on further discussions with the FDA following submission of ARIEL4 OS data previously […]
Less Fluid Not Better for Septic Shock
A more restrictive protocol for IV fluids didn’t reduce mortality for adults in the ICU receiving treatment for septic shock, the CLASSIC trial showed. Restricting IV crystalloid fluids to small boluses only for severe hypoperfusion, to replace documented fluid losses, or for dehydration and electrolyte deficiency for patients who couldn’t take fluids enterally yielded a […]